Two new research involving greater than 1 million US veterans counsel that up to date COVID-19 vaccines proceed to offer significant safety towards extreme sickness.
One examine, printed final week in Vaccine, discovered that the 2025–26 vaccine diminished the chance of emergency division visits by roughly 32% and the chance of hospitalization by roughly 44%. The second examine, printed final week in JAMA Community Open, discovered that the 2025–26 Moderna vaccine supplied higher safety towards medically attended COVID amongst older adults than Pfizer’s vaccine.
Vaccination tied to fewer emergency visits, hospitalizations
Within the first examine, a crew led by researchers from Veterans Affairs (VA) Saint Louis Well being Care System analyzed knowledge from 931,943 veterans who obtained a seasonal flu vaccine from September 21, 2025, to January 31, 2026. Of these, 114,911 obtained a COVID vaccine on the identical day, whereas 817,032 obtained solely the flu vaccine.
Over the course of 180 days, COVID vaccination was related to a 31.7% discount in COVID-related emergency division (ED) visits and a 43.6% lower in hospitalizations. That interprets to roughly seven fewer ED visits and roughly three fewer hospitalizations per 10,000 folks.
Whereas the researchers be aware that absolutely the threat reductions had been modest, the findings “quantify the good thing about vaccination in a lower-incidence season and may inform shared scientific resolution making and seasonal vaccine coverage,” they write.
Moderna vaccine outperforms Pfizer’s model
For the second examine, researchers led by a crew from VA Windfall Healthcare System in Rhode Island in contrast Moderna’s newer mRNA-1283 COVID vaccine with Pfizer/BioNTech’s mRNA COVID vaccine amongst US veterans aged 65 years or older to evaluate whether or not 2025–26 vaccination was related to a decrease threat of COVID an infection that required medical consideration.
Among the many 294,499 individuals, medically attended COVID occurred in 86 of 55,349 mRNA-1283 vaccine recipients (0.16%) and 672 of 239,150 Pfizer vaccine recipients (0.28%). That corresponds to a 35.9% higher relative vaccine effectiveness (VE) for the Moderna vaccine, or 10 fewer medically attended instances per 10,000 vaccinated folks.
The findings counsel that the mRNA-1283 vaccine could supply extra clinically significant safety for older adults at excessive threat of extreme COVID-19 outcomes.
COVID-related hospitalization occurred in 11 mRNA-1283 vaccine recipients (0.02%), in contrast with 114 Pfizer vaccine recipients (0.05%). That represents a higher relative VE of 47.0% for the Moderna vaccine, or two fewer hospitalizations per 10,000 vaccinated folks.
“The findings counsel that the mRNA-1283 vaccine could supply extra clinically significant safety for older adults at excessive threat of extreme COVID-19 outcomes and will inform seasonal vaccine choice,” write the researchers.
The examine was partially funded by Moderna.

